US Oncology Reports Fourth Quarter and Fiscal Year 20...(- - - - (12.9) ...)

Impairment

and

restruct-

uring

charges(3) (6.8) - nm(4) (1.0) nm(4) (15.1) - nm(4)

Total $51.3 $59.5 (13.8) $49.5 3.6 $190.7 $250.0 (23.7)

Adjusted

EBITDA(3) $58.0 $59.5 (2.5) $50.5 14.9 $218.7 $250.0 (12.5)

Net income

(loss) (14.8) 3.3 nm(4) (4.2) nm(4) (35.0) 26.2 nm(4)

Operating

cash flow 74.2 57.1 29.9 (3.9) nm(4) 164.7 20.5 nm(4)

(1) Eliminations represent the sale of pharmaceuticals from our

distribution center (pharmaceutical services segment) to our

practices affiliated under comprehensive service agreements (medical

oncology segment).

(2) Corporate costs relate primarily to general and administrative

expenses in support of our network.

(3) Impairment and restructuring charges and the loss on debt

extinguishment are excluded from Adjusted EBITDA. During the fourth

quarter of 2007, these charges consisted of $0.9 million related to

the medical oncology segment, $1.2 million to the cancer center

services segment and $4.7 million to corporate costs. During 2007,

$1.6 million related to the medical oncology services segment,

$4.2 million to the cancer center services segment and $9.3 million

to corporate costs.

(4) Not meaningful.

Medical Oncology Services

In the fourth quarter of 2007, medical oncology services revenue increased $4.9 million, or 0.9 percent, and EBITDA decreased $5.9 million, or 23.4 percent, compared to the fourth quarter of 2006. The revenue increase reflects an increase in daily visits due to growth in our network of affiliated medical oncologists which was partially offset by reduced utilization of supportive care drugs. The EBITDA decrease is due primarily to reduced
'/>"/>